Nura Bio
Clinical-stage biopharmaceutical company developing neuroprotective small molecule therapies.
Clinical-stage biopharmaceutical company developing neuroprotective small molecule therapies. Headquartered in South San Francisco, CA. Raised $73.8M in Series B funding in June 2026 led by The Column Group.
Biotechnology
📍 South San Francisco, CA
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Nura Bio going public?
No. Nura Bio is private and has not filed to go public. There is no S-1 on file.
What is Nura Bio's valuation in 2026?
No confirmed valuation is on record for Nura Bio. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Nura Bio filed an S-1?
No public S-1 is on file for Nura Bio.
Who are Nura Bio's investors?
Nura Bio's investors include The Column Group, Euclidean Capital, Samsara BioCapital, Sanofi Ventures.
How much has Nura Bio raised?
Nura Bio has raised $73.8M in total across 1 disclosed round, most recently a Series B of $73.8M in Jun 2026.
Is Nura Bio publicly traded — can you buy Nura Bio stock?
No. Nura Bio is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Nura Bio on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
HQ
South San Francisco, CA
Last Round
Series B — $73.8M (Jun 2026) · Lead: The Column Group
Fundraising Status
Series B · $73.8M · 3 mo ago
privateTotal raised $73.8M1 disclosed rounds
Funding History
| Round | Amount | Date | Lead Investor | Post-Money |
|---|
| Series B | $73.8M | Jun 2026 | The Column Group | — |
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
1
1 active · 1 recruiting
Lead phase
Phase 2
most advanced registered study
Focus areas
Amyotrophic Lateral Sclerosis (ALS)
Latest trial start
2026-03-04
Talent Signal
No public careers page or job board could be found for Nura Bio as of 2026-09-14. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.
Investors
The Column Group · Euclidean Capital · Samsara BioCapital · Sanofi Ventures
BiotechnologyBiopharmaceuticalsRecently Funded
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.